Melissa Mercado, DO
Family Medicine · Jersey City, NJNPI 1821587270
Payments from drug & device makers
Across 213 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$502
- Lilly USA, LLC$474
- Novartis$473
- Amgen$409
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$373
- Boehringer Ingelheim$248
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,133100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 29 | $502 |
| Lilly USA, LLC | 32 | $474 |
| Novartis | 31 | $473 |
| Amgen | 20 | $409 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $373 |
| Boehringer Ingelheim | 16 | $248 |
| Madrigal Pharmaceuticals | 2 | $247 |
| Bayer | 11 | $190 |
| Pfizer | 11 | $175 |
| AstraZeneca | 4 | $169 |
| Novo Nordisk | 9 | $166 |
| Abiomed | 2 | $162 |
| AbbVie | 7 | $112 |
| Gilead | 1 | $100 |
| Cardiovascular Systems Inc. | 2 | $92 |
| Merck | 4 | $62 |
| Hologic Sales And Service, LLC | 2 | $51 |
| Amarin Pharma, Inc. | 2 | $29 |
| Astellas Pharma US Inc | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Ardelyx, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,153 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 161 | $148,971 |
| Repatha SureclickEvolocumab | 135 | $89,900 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $88,370 |
| MounjaroTirzepatide | 75 | $86,626 |
| FarxigaDapagliflozin Propanediol | 54 | $52,661 |
| KerendiaFinerenone | 69 | $51,482 |
| TrulicityDulaglutide | 39 | $40,294 |
| EliquisApixaban | 32 | $29,802 |
| RybelsusSemaglutide | 20 | $27,192 |
| JanuviaSitagliptin Phosphate | 32 | $25,867 |
| OzempicSemaglutide | 18 | $20,052 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 27 | $19,654 |
| VascepaIcosapent Ethyl | 48 | $17,933 |
| LinzessLinaclotide | 29 | $17,631 |
| EntrestoSacubitril/Valsartan | 15 | $15,403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Trijardy Xr, Synjardy, Stiolto Respimat | $248 | $185,661210 claims |
| Lilly USA, LLCMounjaro, Trulicity | $474 | $126,920114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $502 | $98,154157 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $169 | $70,592104 claims |
| BayerKerendia | $190 | $51,48269 claims |
| Novo NordiskRybelsus, Ozempic | $166 | $47,24438 claims |
| MerckJanuvia, Janumet, Janumet Xr | $62 | $46,46655 claims |
| PfizerEliquis | $175 | $29,80232 claims |
| AbbVieLinzess | $112 | $17,63129 claims |
| NovartisEntresto | $473 | $15,40315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Jersey City
- Sally MravcakJersey City$64K
- John FritzJersey City$22K
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.